The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)
Status:
Not yet recruiting
Trial end date:
2023-07-17
Target enrollment:
Participant gender:
Summary
This phase 2a trial is a randomized, open-label, parallel-group study in approximately 60
patients with DME to evaluate the efficacy and safety of CU06-1004 orally administered once
daily for 12 weeks. The study will have a 1:1:1 randomization (CU06-1004 100mg: CU06-1004
200mg: CU06-1004 300mg).